| | |
3-year BNED (%)
|
Univariate analysis
|
Multivariate analysis
|
|---|
| |
Variable
| |
p
|
p (95% CI)
|
|---|
|
Gleason Score
|
| |
≤7
|
61
|
0.25
|
0.38
|
| |
>7
|
78
| | |
|
Pathological Stage
|
| |
≤pT3a
|
77
|
0.59
|
0.63
|
| |
pT3a or pT3b
|
64
| | |
|
Surgical Margins
|
| |
compromised
|
67
|
0.65
|
0.5
|
| |
clear
|
74
| | |
|
PNLVSI
|
| |
positive
|
68
|
0.31
|
0.29
|
| |
negative
|
100
| | |
|
Time to recurrence after RP
|
| |
≤12 meses
|
75
|
0.9
|
0.85
|
| |
>12 meses
|
66
| | |
|
PSADT
|
| |
≤4 meses
|
48.4
|
0.01
|
0.01
|
| |
>4 meses
|
75.6
| | |
|
Preradiation PSA
|
| |
≤1 ng/ml
|
75.9
|
0.1
|
0.7
|
| |
>1 ng/ml
|
48.1
| | |
|
Time to radiation after recurrence
|
| |
≤3 months
|
100
|
0.04
|
0.1
|
| |
>3 months
|
60
| | |
|
Clinical tumor on surgical bed
|
| |
Yes
|
80
|
0.4
|
0.46
|
| |
No
|
66
| | |
|
Radiation dose (Gy)
|
| |
≤66 Gy
|
76
|
0.62
|
0.7
|
| |
>66 Gy
|
68
| | |
- CI, confidence interval; PNLVSI, perineural or lymphatic or vascular space invasion; PSADT, PSA doubling time; Gy, Gray.
